Search results for: Multi-Indication Medicines
Filter search results
OHE Welcomes Patrick Holmes to the Board of Trustees
28 March 2022
…expert on developing global policy initiatives to drive affordable patient access to innovative medicines which is core to OHE’s mission.” Patrick Holmes is an industry veteran with over 30 years…
Dr Francois Maignen joins the OHE team as Head of Operational Research and Data Analysis
7 July 2016
…Data Analysis. Francois’s principal areas of expertise are in the clinical development (methodology of clinical trials) and regulation of medicines for human use. Francois worked at the European Medicines…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…were viewed to be especially valuable in the context of rising NHS spending on medicines and the challenges in agreeing a new medicine’s price, which can potentially delay patient access…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…world, medicines reimbursement decisions are based on health technology assessments (HTA) applying cost-effectiveness criteria. Some HTA bodies use a CET as a rule for such decisions. A recent OHE report opens the…
Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe
1 October 2010
…Member States and its impact on patients’ access to medicines Consider how EFPIA could develop responses to these findings to engage in constructive dialogue around the scientific merit and public…
Economic Aspects of the Development of New Medicines
1 January 1981
…challenged by critics such as McKeown (1976); but again it would require another lecture to answer such criticisms. Finally, I have omitted the important role of medicines in animal health….
Medicines, Health and the Poor World
1 April 1982
…the last decade and extending the analysis provided to include an examination of the distribution and use of modern medicines in the ‘third world’. In the light of criticism made…
Costs and Benefits of Regulating New Product Development in the UK Pharmaceutical Industry
3 January 1982
…new medicines. Indeed Hartley and Maynard go so far as to discuss the possibility of a return to a voluntary scheme for the approval of new medicines, such as operated…
Impact of New Medicines on Health Care Costs
1 March 1989
…referred to in the Box on page 2. This Briefing, however, refers only to health service costs and to the direct savings which medicines can yield within the Health Service….